Clinical Trial Update: Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing whether GM-CSF can restore neutrophil phagocytosis in critically ill patients, including those with sepsis and immunosuppression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness
• Immunosuppression
• Sepsis

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust | Conditions: Critical Illness, Sepsis | Phase 1, Phase 2 | Status: COMPLETED